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ABSTRACT 
Master thesis, Programme in Medicine. 
Urinary tract infections – Etiology, antibiotic susceptibility and treatment in surgical patients 
in Nepal. Adam Oscarson, University of Gothenburg, Sweden 2014. 
 
Background: Urinary tract infections (UTI) are among the most common postoperative 
nosocomial infections and the second most common reason for empirical antibiotic treatment. 
Optimal treatment could decrease mortality and morbidity in surgical patients and play a vital 
role in combating the ongoing crises of increasing antibiotic resistance. 
 
Aims: To study the pathogens and their antibiotic susceptibility in urinary cultures from a 
surgical clinic in a tertiary care hospital in Nepal; and to study the use of antibiotics, 
rationality of antibiotic treatment and surgical risk factors for urinary tract infection. 
 
Methods: All urinary cultures from the surgical clinic during 18 month were reviewed. In 
addition, 50 patients had their medical chart reviewed for treatment and risk factors. 
 
Result: E. coli was the most common bacteria (74 %). The overall level of resistance to 
commonly used antibiotics were high in all pathogens. Amikacin and nitrofurantoin were 
generally the antibiotics with lowest rates of resistance. Aminoglycosides and 
fluoroquinolones were the most often used antibiotics. In first-line treatment, only 55 % of 
cases were given at least one antibiotic to which the bacteria was sensitive. A statistical 
significant higher resistant to both ciprofloxacin and cefotaxime were found in cultures from 
the surgical ward compared to the surgical reference clinic (P = 0.02 and P = 0.002), and to 
ciprofloxacin in cases with indwelling urinary catheter compared to cases without indwelling 
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urinary catheter (P = 0.005) and in cases with previous admittance to hospital compared to 
cases without previous admittance to hospital (P = 0.008).  
 
Conclusions: This study found an exceptional high rate of antibiotic resistance, and a low rate 
of effective empirical antibiotic treatment. Guidelines on antibiotic treatment are needed, and 
for empirical treatment of nosocomial UTI an increased use of nitrofurantoin and amikacin is 
recommended, rather than cephalosporins and fluoroquinolones. 
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BACKGROUND 
Antibiotic resistance 
Antibiotic resistance (ABR) is a normal evolutionary process. In environments where 
antibiotics are abundant and thus constitute an important selection pressure, mutations that 
entail resistance provides a competitive advantage to the microbes carrying it and are 
therefore favoured in the natural selection. The vast use of antibiotics in hospitals and the 
community – as well as in agriculture – over the last decades have accelerated this process to 
a point where ABR have emerged as a global health problem. Widespread resistance to 
antibiotics is not only creating difficult-to-treat infections associated with high mortality, but 
also threatening major progresses in modern medicine like major surgery and cancer 
chemotherapy, as well as having social and economic impact [1, 2]. Bacteria with resistance 
to broad-spectrum antibiotics are increasing, and with the emergence of multidrug-resistant 
bacteria there is an increasing fear that we are heading towards a post-antibiotic era [2-4]. 
Resistance to antibiotics are now found all over the world, and have even been found in the 
Arctic – a region without selection pressure for resistance development [5]. Resistance is 
spread between bacteria, humans and regions by means of transmission of resistance genes 
between bacteria (e.g. plasmids and transposons), poor sanitation and hygiene in hospitals and 
communities, and global travel, trade and migration.  
 
Since the turn of the millennium, bacteria of the family Enterobacteriaceae producing 
extended-spectrum β-lactamases (ESBL) – enzymes providing resistance to almost all β-
lactam antibiotics (like penicillin and cephalosporins) except carbapenems – have emerged as 
an important cause of infections, including urinary tract infections (UTI). They have since 
spread to all over the world and are often associated with multi-drug resistance including 
resistance to co-trimoxazole, aminoglycosides and ciprofloxacin – important antibiotics in the 
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(empirical) treatment of UTI [6]. Since a few years back, we also see an alarmingly rapid 
world-wide dissemination of resistance against carbapenems [7]. One example is the New 
Delhi metallo-β-lactamase 1 (NDM-1) gene, first identified in Sweden 2008 in a urine culture 
from a patient previously hospitalized in New Delhi [8]. Within a few years, the gene had 
spread to large parts of the world [9-11]. The NDM-1 gene is exhibiting several worrisome 
characteristics like being associated with plasmids carrying high number of genes mediating 
resistance to virtually all antibiotics but tigecycline, colistin and fosfomycin, as well as being 
found in many unrelated species of bacteria including Klebsiella pneumoniae (a common 
nosocomial pathogen) and Escherichia coli (the main community-acquired human pathogen) 
[9, 12], also the two main pathogens of UTI [13].  
 
Selection of resistance genes and spread of bacteria with ABR is mainly a local process, with 
practices in individual hospitals and communities playing a critical role [2]. Resistance genes 
may be transferred to bacterial spices capable of causing other kinds of infections than the 
original one. Successful genes may then be further selected and transferred to new hosts, and 
in that process being amplified and established as important resistance genes, especially if the 
selection pressure of antibiotics continues. They can then spread through different kinds of 
bacteria nearly everywhere through the world's interconnecting commensal, environmental, 
and pathogenic bacterial populations. As an example, resistance to sulfonamides has been 
found throughout the world encoded by only 2 resistance genes [14].  
 
The combination of highly susceptible patients, intensive and prolonged antibiotic use and 
cross-infections make hospitals a hotspot for both evolution and spread of ABR. Emergence 
of resistant strains in hospitals occurs when a patient infected with a resistant bacteria is 
transferred to the hospital from another facility, by patient-to-patient transfer, through 
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selection caused by antibiotic use, and by transfer of resistance genes. Overcrowding, limited 
capacity and poor sanitation make the situation worse in many low and middle-income 
countries (LMICs). Healthcare-associated infections are a problem worldwide, adding not 
only to the burden of both infections and ABR but also constituting a major threat to patients' 
safety. A review [15] found the pooled prevalence of overall healthcare-associated infection 
in LMICs to be 15.5 per 100 patients, twice as much as in Europe (7.1 per 100 patients) [16]. 
Gram-negative bacteria represented the most common isolates in nosocomial infections. 
 
The rate of resistance varies widely between bacteria, class of antibiotic, countries, patient 
categories and healthcare facilities. Different levels of resistance between and within 
countries might be explained by differences in consumption [17]. Worldwide the antibiotic 
consumption is increasing, including carbapenems [2]. The use of non-prescription antibiotics 
are common in many parts of the world and outside of northern Europe and North America 
non-prescription use account for 19 - 100 % of antimicrobial use [18]. Increasing non-
prescription use of antibiotics has been associated with clinically important ABR, including 
high levels of resistance in E. coli in urinary cultures [18-20]. In countries with limited and/or 
poor access to healthcare, a ban on over-the-counter antibiotics might impede vital access to 
antibiotics. Especially in LMICs this provides a dilemma on how to ensure access to 
antibiotics without excessive or inappropriate use. The access and excess dilemma is however 
not restricted to non-prescription use (or to the LMICs) since prescribed antibiotic could be 
unnecessary or suboptimal, or patients in need are not given treatment due to therapeutic, 
financial and structural barriers. As an example, less than a third of children in LMICs with 
suspected pneumonia receive potentially life-saving treatment with antibiotics at the same 
time as antibiotics are too often prescribed for diarrhoea instead oral rehydration salts and 
zinc [21, 22].  
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Both the prevalence of ABR around the world, and the burden of it, is inadequately studied [1, 
2]. Most studies are carried out in a hospital setting, often with cultures from severely ill 
patients where first-line treatment have failed. Community-acquired infections and infections 
treated in out-patient-care are underrepresented. This may exaggerate the rates of ABR and 
further drive the use of broad-spectrum antibiotics, which in turn may further accelerate the 
evolution and spread of resistance [1]. The burden of ABR is thought to the result of longer 
duration of illness and higher mortality, increasing costs of treatment and inability to perform 
procedures that require antibiotics to prevent infections [2]. An often cited study from 2007 
[23] estimated that each year about 25 000 patients in the European Union, Iceland and 
Norway die from an infection with resistant bacteria, and that ABR result in extra healthcare 
costs and productivity losses of at least EUR 1.5 billion each year. Although poorly studied, 
the higher prevalence of infectious diseases and restricted access to healthcare and second-
line antibiotics in LMICs, it is estimated that the burden probably is higher than in high-
income countries, and since two thirds of childhood mortality is associated with infections, 
children are probably more affected than adults [2, 24]. Adding onto the already complex 
issue of ABR, the situation in many LMICs is often further aggravated by poverty, which 
leads to poor sanitation, hunger and malnutrition, inadequate access to drugs, poor and 
inadequate health care systems, civil conflicts and bad governance [25]. Also, the problem of 
resistance might not be adequately recognised by most stakeholders as there are higher 
priorities to address such as provision of basic health care or sanitation. 
 
As have been pointed out above, we are now in a situation where ABR is found worldwide, 
and in many places constitute an important medical problem. There is no single, easy solution 
to this problem, but rather a need for a multitude of actions and strategies. Effective infection-
control practices and good hygiene are the foundation in controlling the spread of 
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antimicrobial resistance in healthcare settings. In communities, reduction in infections and 
decreased colonisation and transfer of resistant bacteria and resistance genes can be achieved 
through reduction of poverty, improved sanitation and access to clean water [2]. Improvement 
in rational use of antibiotics through so called antibiotic stewardship programs with education, 
treatment guidelines, restricted availability to certain antibiotics, surveillance of ABR and 
antibiotic usage, and post prescription audit and feedback of antibiotic use, can decrease the 
emergence of antimicrobial resistance and reduce colonization or infection with resistant 
bacteria [26, 27]. As an example, a study [28] done in a university-affiliated hospital found 
that a new antibiotic guideline that reduced the use of cephalosporins by 80 % led to a 44 % 
hospital-wide decrease in ESBL-producing Klebsiella isolates within 1 year. Antibiotic 
stewardship programs should also be expanded to LMICs, primary care settings and the 
community, and adjusted to local conditions. Where prescriptions of antibiotics are a source 
of revenue – either for individuals or institutions such as hospitals – efforts should be made to 
separate prescription and dispensing [2]. New antibiotics needs to be developed. Since the 
1970:s only two new classes of antibiotics have reached the market, and the number of new 
analogues are decreasing. At the moment though, the pipeline for new antibiotics is almost 
dry [2]. However, resistance will eventually arise to all antibiotics, so new antibiotics needs to 
be used with caution and be paired with effective stewardship programmes. To avoid 
pharmaceutical companies maximising profits on new antibiotics by selling large quantities, 
delinkage of revenues and the use of the product is needed and instead new models of income 
needs to be developed, as well as models permitting global access at affordable prices [2, 29] . 
In the meantime – while we wait for new antibiotics to appear – new approaches are needed to 
address the problem. Studied today are: anti-virulence approaches, phage therapy, therapeutic 
antibodies, drugs based on antimicrobial peptides, potentiators of traditional antibiotics (like 
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the β-lactamase inhibitors already in clinical use) and efflux pump inhibitors, and antibacterial 
biomaterials [30].  
 
Antibiotic resistance and its consequences a serious threat to public health akin to that of 
anthropogenic global warming, and calls for concerted global action. We need a worldwide 
coalition of governments with a strong representation from LMICs, WHO and other UN 
agencies, other international bodies, science academies, development aid agencies, civil 
society organisations and pharmaceutical companies to develop a global plan to tackle the 
antibiotic crisis. 
 
Urinary tract infections 
Urinary tract infections are among the most common bacterial infections in humans, both as 
community-acquired and healthcare-associated infections. It is the most common nonsurgical 
nosocomial infection in postoperative patients and the second most common healthcare-
associated infection [15, 31]. As the second most common reason for empirical antibiotic 
treatment, UTI is a major driver of antibiotic usage globally [32]. It have a wide spectrum of 
severity – and even though a usually benign infection – the occurrence of a UTI in a surgical 
patient is associated with a threefold increase in death during hospitalization [33]. Hence, the 
prevention and treatment of UTI is therefore of great concern for the survival and wellbeing 
of the individual surgical patient.  
 
Bacteriuria – the presence of bacteria in the urine – can be subdivided into the following 
categories and definitions [13, 32]: 
 Asymptomatic bacteriuria (ABU) – bacteriuria in the absence of symptoms. Should 
generally not be treated. 
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 Symptomatic bacteriuria – bacteriuria in the presence of typical symptoms for UTI. 
 Lower UTI – the infection is localized in the lower urinary tracts, i.e. the bladder and 
urethra. Fever is uncommon and the general condition of the patient is usually 
unaffected. 
 Upper UTI – the infection is localized to the upper urinary tracts, also called 
pyelonephritis; a much more severe condition than lower UTI, and frequently causes 
sepsis (urosepsis). 
 Complicated UTI – upper UTI and/or UTI in individuals with predisposing factors 
such as structural and functional abnormalities in the urinary tracts, metabolic 
disorders or impaired immunity. UTI in children and men are often considered to be 
complicated UTI, and are more often caused by multi-resistant organisms.  
 
E. coli is by far the most common pathogen, often accounting for more than 80 % in 
uncomplicated UTI, although most studies are done in high- or middle-income countries. 
Other pathogens (so-called secondary pathogens such as Klebsiella spp, Enterobacter, 
Proteus spp) and are usually found in patients with complicated UTI. Generally, these 
pathogens have a decreased susceptibility to many antibiotics [13]. 
 
Predisposing factors for UTI include structural and functional abnormalities, foreign bodies, 
metabolic abnormalities, impaired immunity and urological surgery and instrumentation [32]. 
Indwelling catheter use is a known risk factor for UTI, with duration of catheterization as the 
single most important risk factor [32].The bacteria is often of several different species, often 
multi-resistant [13]. Catheter-associated UTI make up a large proportion (approximately 30 - 
40 %) of the healthcare-associated infections, and as many as 10 % of patients in a urological 
wards have healthcare-associated complicated infections [32]. 
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Nepal 
Nepal is a small country in Asia, situated on the southern slopes of Himalaya. It is one of the 
world’s poorest countries, ranking 157th out of 187 countries on the Human Development 
Index. A third of the population lives below the poverty line, and the income gaps are huge. It 
is also one of the world’s least urbanized countries. Instability and political unrest have 
afflicted Nepal for decades, and a decade-long civil war ended in 2006. The public health 
situation is deficient with widespread infectious diseases, high infant mortality rate (46/1 000 
in 2013) and a shortage of healthcare resources and staff. However, despite the numerous 
challenges, significant improvements in both poverty reduction and health have been made in 
the last decades [34, 35]. 
 
Studies and reports done in hospital settings (with a presumed dominance of complicated 
UTI) in Nepal shows a high degree of resistance in uropathogens: 19.2 % - 48 % for E. coli 
and Klebsiella spp resistant to third generation cephalosporins [36-38], 21.6 % - 35 % for E. 
coli and Klebsiella spp resistant to fluoroquinolones [36, 38]. These findings are in line with 
figures from WHO, however they reported a resistance rate of E. coli to fluoroquinolones of 
64.3 % [1]. 
 
AIMS 
This is a hospital-based retrospective descriptive study in two parts that aims to study:  
1) Pathogens and antibiotic susceptibility among patients with presumed complicated 
UTI at a surgical clinic in a tertiary care hospital in Nepal.  
2) The use of antibiotics, rationality of antibiotic treatment and surgical risk factors.  
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METHODS  
The study was performed at Patan Hospital, a tertiary care hospital located in Patan (adjacent 
to Kathmandu), Nepal. It is one of the largest hospitals in the country, treating 320 000 
outpatients, 20 000 inpatients and performing 10 000 operations annually. It is run by Patan 
Academy of Health Sciences, an autonomous, not-for-profit public institution of higher 
education. It accepts patients from all over the country offering subsidized or free treatment to 
patients without the ability to pay full price for the healthcare given, thus focusing on Nepal’s 
rural poor [39]. 
 
In Part 1, the log books of urine cultures at the microbiological department were searched 
manually and all records of urine cultures from either the surgical ward or the surgical 
reference clinic from 2069-03-15 to 2070-09-15 according to Nepali calendar (2012-07-01 to 
2013-12-31 in Gregorian calendar) were noted. A total number of 774 cultures from 715 
unique patients were found. Since no record of whether the urine sample consisted of mid-
stream or catheter urine were kept, it was not possible in the first part of the study to 
differentiate between these two procedures of urine culture. Growth with more than 10 000 
colony forming units/ml (CFU/ml) were recorded by the laboratory and thus included in the 
study. Coagulase negative staphylococci, non-haemolytic streptococci and yeast cells were 
regarded as contamination. No test for ESBL was performed. Comparisons with results from 
blood cultures were not done. 
 
For Part 2, all cultures with a growth of more than 100 000 CFU/ml and from a patient with a 
six digit hospital number (which means that the medical chart were kept in the hospital’s 
archive) during the study period where then selected for review of their medical chart. With 
this criteria 70 cases were found (a case was defined as an independent illness episode), and 
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of these 50 cases (71 %) of 48 unique patients (two patients occurring two times) were found 
and retrieved in the hospital’s archive; representing 37 % of cultures with significant growth 
and 6 % of total cultures. In accordance with other studies from Nepal [36-38], and local 
hospital definition of UTI, over 100 000 CFU/ml were considered significant growth and 
hence this definition is used in this part of the study. 
 
The surgical ward at the hospital provided care for in-patients requiring 24-hour medical 
attention, while the surgical reference clinic treated out-patients coming to appointments with 
the doctor, e.g. postoperative follow-ups. From the surgical ward came 39 % (301 cultures) of 
total cultures, 32 % (44 cultures) in Part 1 and 40 % (20 cases) in Part 2, and from the surgical 
reference clinic came 61 % (473 cultures) of total cultures, 68 % (92 cultures) in Part 1 and 60 
% (30 cases) in Part 2.  
 
The distribution of E. coli were 74 % (101 cultures) in Part 1 and 72 % (36 cases) in Part 2; 
for non-E. coli cultures those numbers were 26 % (35 cultures) and 28 % (14 cases), 
respectively. The relatively good correlation between total cultures, Part 1 and Part 2 could 
indicate that the cases in Part 2 compose a representative sample. The large dropout rate was 
however a major limitation.  
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Figure 1. Data collection procedures. See text for more information. 
 
Patients in Part 2 
The number of female cases was 22, and male cases 28. Distribution of age and sex is 
presented in figure 2 below. No interviews were done with the patients, and all patient data 
are derived from medical charts. From the surgical ward came 20 cases (40 %) and from the 
surgical reference clinic 30 cases (60 %). 
 
Positive cultures - Part 1
136
Negative cultures or 
contamination
638
All cultures
774
> 105 CFU/ml + six-digit 
hospital number
70
Not meeting criteria for 
review of medical chart
66
Medical chart found in 
archive - Part 2
50
Medical chart not found 
in archive
20
16 
 
 
Figure 2. Distribution of age and sex. Numbers are number of cases. One female patient was lacking information about age 
and is excluded in this figure. 
 
The urine samples were inoculated onto agar plates (blood agar and MacConkey agar) using 
calibrated loop. After incubation the plates were examined for bacterial growth and 
quantified. For positive cultures, bacterial identification was done using morphological 
characteristics, Gram staining and various biochemical tests. The sensitivity testing was done 
using the Kirby-Bauer disk diffusion susceptibility test. 
 
Statistics 
All documentation in the hospital were handwritten and in English. Information from the 
logbook of the laboratory was transferred into Microsoft Access 2013, and information from 
the medical charts was noted in Microsoft Excel 2013. Analyses were done in Microsoft 
Excel 2013 and all numbers have been rounded off to integers. Statistical analyses for P-
value, risk ratio and 95 % confidence limits were done by chi square test with the software 
OpenEpi: Open Source Epidemiologic Statistics for Public Health [40].  
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ETHICS 
Ethical approval was given by the Institutional Review Committee of Patan Academy of 
Health Sciences and the form is attached as Appendix A. 
 
RESULTS 
Part 1 
Antibiotic susceptibility 
In Part 1, 136 cultures (18 %) with nine different species of bacteria were found (figure 3). 
The most common pathogen was Escherichia coli (E. coli, 74 %), the second most common 
was Klebsiella spp (12 %). Of all cultures, 110 (14 % of total) had more than 100 000 
CFU/ml, 75 % of those were E. coli (69 % from the surgical ward, 77 % from the surgical 
reference clinic [no statistical significance]). Worth noting is that no culture of Salmonella 
spp were found, despite being a common cause of blood stream infections in Nepal [41, 42]. 
 
 
Figure 3. Bacterial species in positive cultures. Numbers are number of cultures, in total 136 cultures. S. aureus - 
Staphylococcus aureus.  
 
18 
 
The mean susceptibility of all the cultures combined is presented in figure 4. One culture each 
of E. coli and Acinetobacter spp have been omitted since susceptibility tests were not 
performed on these, giving a total of 134 cultures. 
 
 
Figure 4. The susceptibility of all cultures combined to common antibiotics. Numbers are number of cultures. Not tested - no 
susceptibility test done. 
 
Cultures with a high degree of resistance to common antibiotics were tested for further 
antibiotics (table 1). It is however important to notice that these antibiotics were only tested 
on a small number of cultures. 
 
Susceptibility of all positive cultures 
 Resistant Intermediate Sensitive Total 
Meropenem 4 (40 %) 2 (20 %) 4 (40 %) 10 
Imipenem 4 (36 %) 1 (9 %) 6 (55 %) 11 
Piperacillin-Tazobactam 3 (75 %) 0 1 (25 %) 4 
Colistin 1 (11 %) 0 8 (89 %) 9 
Tigecycline 1 (17 %) 0 5 (83 %) 6 
 
Table 1. Extended susceptibility testing of all cultures combined. Numbers are number of cultures. 
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The susceptibility of E. coli to common antibiotics is shown in figure 5. For one culture of E. 
coli no susceptibility test was done, and this culture have been omitted from further analyses. 
Hence, the susceptibility analyses are based on 100 cultures of E. coli. Table 2 shows the 
extended susceptibility testing. 
 
 
Figure 5. The susceptibility of E. coli to common antibiotics. The digits in the graph show the number of cultures. 
 
E. coli susceptibility 
 Resistant Intermediate Sensitive Total 
Meropenem 3 (50 %) 0 3 (50 %) 6 
Imipenem 4 (57 %) 0 3 (43 %) 7 
Piperacillin-Tazobactam 2 (67 %) 0 1 (33 %) 3 
Colistin 1 (17 %) 0 5 (83 %) 6 
Tigecycline 0 (0 %) 0 3 (100 %) 3 
 
Table 2. Extended susceptibility testing of E. coli. 
 
Figure 6 shows the susceptibility to common antibiotics of Klebsiella spp, and table 3 shows 
the extended susceptibility testing. 
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Figure 6. The susceptibility of Klebsiella spp to common antibiotics. The digits in the graph show the number of cultures.  
 
Klebsiella spp susceptibility 
 Resistant Intermediate Sensitive Total 
Meropenem 0 2 (67 %) 1 (33 %) 3 
Imipenem 0 1 (33 %) 2 (67 %) 3 
Piperacillin-Tazobactam 1 (100 %) 0 0  1 
Colistin 0 0 2 (100 %) 2 
Tigecycline 0 0 2 (100 %) 2 
 
Table 3. Extended susceptibility testing of Klebsiella spp. 
 
Susceptibility of non-E. coli pathogens combined are presented in figure 7 and table 4. One 
culture of Acinetobacter spp have been omitted since susceptibility test were not performed, 
giving a total of 34 cultures. 
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Figure 7. The susceptibility of non-E. coli pathogens to common antibiotics. The digits in the graph show the number of 
cultures. Not tested - no susceptibility test done.  
 
Non-E. coli susceptibility 
 Resistant Intermediate Sensitive Total 
Meropenem 1 (25 %) 2 (50 %) 1 (25 %) 4 
Imipenem 0 1 (25 %) 3 (75 %) 4 
Piperacillin-Tazobactam 1 (100 %) 0 0 1 
Colistin 0 0 3 (100 %) 3 
Tigecycline 1 (33 %) 0 2 (67 %) 3 
 
Table 4. Extended susceptibility testing of non-E. coli pathogens. 
 
Further analyses were done to investigate the susceptibility of all the tested cultures to the 
commonly used antibiotics in treatment of UTI at PH [43]. Cultures not tested for some or any 
of the drugs have been omitted. The empirical treatment of uncomplicated UTI is usually 
fluoroquinolones such as ciprofloxacin and ofloxacin, or sometimes cefixime (a third 
generation cephalosporin). For complicated UTI, empirical treatment consists of either 
fluoroquinolones, third generation cephalosporins (usually ceftriaxone), and/or 
aminoglycosides (gentamycin/amikacin), depending on the patient’s condition.  
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Bacteria resistant or intermediate to both ciprofloxacin and cefotaxime were found in 72 
cultures (54 %). Furthermore, of 71 tested cultures, 20 (28 % of these, 15 % of total) were 
also resistant to amikacin (figure 8). 
 
 
Figure 8. Resistance (as either resistant or intermediate) to ciprofloxacin, cefotaxime and amikacin by bacterial species. 
Percentage of total number per species, and number of cultures, is shown. 
 
Of these, 10 were tested for imipenem (a carbapenem), which gave four resistant, one 
intermediate and five sensitive cultures. Of the five resistant or intermediate cultures, four 
were E. coli and one Klebsiella spp. Of these, four were tested for colistin and three for 
tigecykline – all of these were found to be sensitive. 
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Part 2 
Patient characteristics  
The bacteria found in Part 2 are presented in table 5. 
 
Culture result 
 Number of cases 
Acinetobacter spp 1 (2 %) 
Citrobacter freundii 1 (2 %) 
E. coli 36 (72 %) 
Enterobacter 2 (4 %) 
Klebsiella spp 5 (10 %) 
Morganella morganii 1 (2 %) 
Proteus spp 2 (4 %) 
Pseudomonas spp 2 (4 %) 
 
Table 5. Pathogens in Part 2.   
 
There were 27 (54 %) cases were signs or symptoms of UTI were recorded. Information about 
clinical signs or clinical evaluation for the other 46 % of the patients was not mentioned in the 
medical records. Twenty cases (40 %) had an indwelling urinary catheter at the time the urine 
sample was taken, 23 % of female cases and 54 % of male cases. Cases with indwelling 
urinary catheter had a statistically significant increased likelihood of a non-E. coli pathogen 
(figure 9). No statistically significant differences in pathogens were seen between female and 
male cases, or in cases younger or older than 50 years. 
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Figure 9. E. coli and non-E. coli pathogens by indwelling urinary catheter. Numbers are percentage of cases within each 
groups. P = 0.02, RR = 2.7, 95 % CI = 1.06 - 6.88. 
 
Previous surgery or instrumentation of the urinary tracts had been done in 18 cases (36 %), 
five cases (10 %) had history of gynaecological surgery, 17 cases (34 %) had undergone any 
kind of surgery within the preceding three month and 24 cases (48 %) had been admitted to 
hospital within the preceding six month. Twenty-two cases (44 %) had been prescribed 
antibiotics within the preceding three months, 16 (73 %) of these cases had received two or 
more different classes of antibiotics (with a maximum of five classes). The different 
antibiotics prescribed and total number of occasions can be seen in table 6.  
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Previously prescribed 
antibiotics 
 Number of occasions 
Amikacin 3 
Azithromycin 1 
Cefadroxil 1 
Cefepin 1 
Cefixime 2 
Cefotaxime 2 
Ceftriaxone 7 
Chloramfenicol 1 
Ciprofloxacin 5 
Cloxacillin 4 
Co-trimoxazole 2 
Gentamycin 4 
Levofloxacin 1 
Metronidazol 4 
Nitrofurantoin 1 
Ofloxacin 11 
 
Table 6. Antibiotics previously prescribed (within the preceding three month) and the total number of treatment episodes. 
 
Nineteen cases (38 %) had been treated for UTI in the preceding 12 month, seven (37 %) of 
these cases more than once (two cases lacked record of number of previous UTI:s). Thirteen 
cases (26 %) had benign enlargement of prostate, five cases (10 %) had nephrolithiasis and 
one case (2 %) a bladder stone when the urine sample was taken.  
 
The primary diagnosis is displayed in table 7, the associated pathogens in figure 10. The 
secondary diagnosis are shown in table 8. 
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Primary diagnosis 
 Number 
of cases 
 Number 
of cases 
Infection; other 1 Infection, total 14 (28 %) 
Infection; other, surgical, UTI 1   
Infection; other, UTI 1   
Infection; SSI 2   
Infection; surgical 3   
Infection; UTI 4   
    
Internal medicine condition 1 Internal medicine condition, total 2 (4 %) 
Internal medicine condition – Surgical 
condition – Infection; other, UTI 
1   
    
Surgical condition 9 Surgical condition, total 12 (24 %) 
Surgical condition; trauma 2   
    
Urological condition 18 Urological condition, total 22 (44 %) 
Urological condition; trauma 3   
Urological condition – Infection; UTI 1   
  Records not available 3 (6 %) 
 
Table 7. Primary diagnosis. Total numbers can include more than one case, hence adding up to more than 100 %. Records 
not available - no record of primary diagnosis was found in medical chart. 
 
 
Figure 10. E. coli and non-E. coli pathogens in the main primary diagnoses (hence the different numbers compared to table 
7). The differences between the pathogen groups were statistically significant for surgical- and urological condition vs 
infection and internal medicine condition (P = 0.001). 
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Secondary diagnosis 
 Number of cases, total 
Cancer 1 
Infection 2 
Internal medicine condition 7 
Orthopedic condition 1 
Paralytic 4 
Previous cancer 2 
Psyciatric condition 1 
Surgical condition 1 
Urological condition 20 
 
Table 8. Secondary diagnosis. NB! Some cases lacked record of secondary diagnosis, while other had more than one. 
 
Treatment 
To evaluate the antibiotic treatment of UTI and the rationality of the treatment proved 
difficult, mainly due to that many patients were treated for other conditions and infections 
than UTI, and to receive clarity on the indication(s) for each antibiotic was most often not 
possible. Also, only the date of the first dose was noted, and duration of each antibiotic was 
not included in the study. This made it difficult to determine if patients receiving more than 
one antibiotic were treated with multiple antibiotics simultaneously or if the antibiotic 
treatment was changed. Also, only new kinds of antibiotics to the patient were noted. 
 
In total the patients were prescribed 87 antibiotics (table 9). In seven cases (14 %) there was 
no record of any antibiotic treatment at all. However: in 13 cases (26 %) three or more (with a 
maximum of six) different antibiotics were given. 
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All antibiotics prescribed 
 Number of occasions 
Amikacin 9 
Amoxicillin 1 
Azithromycin 2 
Cefazoline 1 
Cefixime 2 
Cefpodoxime 1 
Ceftriaxone 6 
Ciprofloxacin 14 
Cloxacillin 5 
Co-
trimoxazole 
3 
Gentamycin 9 
Metronidazol 7 
Nitrofurantoin 5 
Ofloxacin 22 
 
Table 9. All antibiotics prescribed in the study. 
 
The combinations used as first-line and second-line treatment is shown in table 10 and table 
11, and the susceptibility to the antibiotics in first-line treatment in figure 11. First-line 
treatment were defined as antibiotics prescribed within five days before and seven days after 
culture sample was taken, second-line treatment as a new prescription of antibiotic after three 
days. Note however that “sensitive” only means that at least one antibiotic prescribed were 
effective against the bacteria in the culture, and it is not possible to say for how long time that 
antibiotic was used. It is worth noting however, that of the cases receiving antibiotic 
treatment, only 55 % of cases got at least one antibiotic to which the bacteria was sensitive. 
No statistical significant difference in treatment effectiveness (measured as resistant, not 
effective, and not tested vs sensitive) between cases in the surgical ward and cases in the 
surgical reference clinic could be seen. 
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First-line treatment 
 Number of occasions 
Amikacin 3 
Amikacin, Ofloxacin 2 
Azitromycin 1 
Cefazoline, Gentamycin 1 
Cefexime 1 
Cefpodoxime, Azithromycin, Amikacin 1 
Ceftriaxone, Cefixime 1 
Ceftriaxone, Ciprofloxacin, Metronidazol 1 
Ceftriaxone, Cloxacillin, Amikacin 1 
Ceftriaxone, Metronidazol, Amikacin 1 
Ciprofloxacin 5 
Ciprofloxacin, Gentamycin, Ofloxacin 1 
Ciprofloxacin, Metronidazol 2 
Ciprofloxacin, Ofloxacin 3 
Cloxacillin 1 
Cloxacillin, Metronidazol 1 
Gentamycin 2 
Gentamycin, Ofloxacin 2 
Nitrofurantoin 2 
Ofloxacin 9 
Ofloxacin, Nitrofurantoin 1 
 
Table 10. First-line treatments and number of occasions used. Defined as antibiotics prescribed within five days before and 
seven days after culture sample was taken. 
 
 
Figure 11. Susceptibility to any of the antibiotics prescribed as first-line treatment. Numbers are number of cases. Resistant - 
resistant to all antibiotics. Sensitive - sensitive to at least one antibiotic. Not prescribed - no antibiotic were prescribed in 
relation to the urine culture sample taken. No effect - all antibiotic(s) were of a class with no effect on the bacteria. Not 
tested - kind of antibiotic not tested for susceptibility. 
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Second-line treatment 
 Number of occasions 
Amikacin (S), Co-trimoxazole (S) 1 
Ciprofloxacin (R) 1 
Co-trimoxazole (S) 2 
Nitrofurantoin (S) 1 
Ofloxacin (R), Nitrofurantoin (S) 1 
Ofloxacin (S) 1 
 
Table 11. Second-line treatment and number of occasions. Defined as a new prescription of antibiotic after three days. 
 
Out of the 42 cases in table 10 (first-line treatment), 7 cases (17 %), received second-line 
treatment, which has been interpreted as treatment failure.  
 
Antibiotic susceptibility in various risk factors 
Finally, the antibiotic susceptibility to ciprofloxacin and cefotaxime were compared in 
different sub-groups in the study. Ciprofloxacin and cefotaxime were regarded as most 
relevant antibiotics to compare since they were the most common empiric treatment for UTI 
(amikacin excluded due to low overall resistance rate). Intermediate cultures have been 
considered resistant in the statistical calculations.  
 
In Part 1, a statistical significant higher resistant to both ciprofloxacin and cefotaxime were 
found in cultures from the surgical ward compared to cultures from the surgical reference 
clinic (figure 12). In Part 2, statistical significant differences were found for resistance to 
ciprofloxacin (but not to cefotaxime) between cases with or without indwelling urinary 
catheter (figure 13), and in cases with previous admittance to hospital (figure 14). No 
statistically significant increase in resistance to either ciprofloxacin or cefotaxime was found 
in cases with previous surgery of the urinary tract, urological condition as primary diagnosis, 
previous antibiotic treatment, and previous UTI. 
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Figure 12. Susceptibility to ciprofloxacin and cefotaxime in cultures from the surgical ward (SW) and the surgical reference 
clinic (SRC). Numbers are percentage of cases within each groups. Ciprofloxacin: P = 0.02, RR = 1.27, 95 % CI = 1.04 - 
1.55; Cefotaxime: P = 0.002, RR = 1.54, 95 % CI = 1.18 - 2.01 
 
 
Figure 13. Susceptibility to ciprofloxacin and cefotaxime by indwelling urinary catheter. Numbers are percentage of cases 
within each groups. Ciprofloxacin: P = 0.005, RR = 1.5, CI = 1.12 - 2.01; Cefotaxime: P = 0.21, RR = 1.18, 95 % CI = 0.82 
- 1.72 
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Figure 14. Susceptibility to ciprofloxacin and cefotaxime in cases by previously admittance within the preceding six month. 
Numbers are percentage of cases within each groups. Ciprofloxacin: P = 0.008, RR = 1.49, CI = 1.07 - 2.07; Cefotaxime: P 
= 0.35, RR = 1.08, 95 % CI = 0.74 - 1.58 
 
DISCUSSION 
The main finding in this study were the exceptionally high levels of resistance to virtually all 
clinically relevant antibiotics. Highest degrees of resistance were found in fluoroquinolones, 
the most commonly prescribed antibiotics in this study. Amikacin and nitrofurantoin proved 
to be the antibiotics with the most favourable resistance rates (nitrofurantoin only for E. coli). 
Although carbapenems were tested in a too limited number of cultures to draw reliable 
conclusions, 50 % were resistant. In the light of that previous studies in Nepal have found no 
resistance to carbapenems, this raises a warning that resistance to carbapenems might be on 
the rise in Nepal. Throughout monitoring of local antibiotic resistance is of paramount 
importance to tackle this problem. 
 
The other main finding was the ineffectiveness of the first line treatments. Only 55 % of cases 
treated with antibiotics were treated with at least one antibiotic that were effective against the 
bacteria. In many cases, the effective antibiotics were only aminoglycosides. The high rates of 
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resistance compose a formidable challenge to effective empirical treatment. This finding 
emphasizes the need of local and national clinical guidelines for empirical treatment as well 
as the monitoring of bacterial cultures in postoperative infections.   
 
Looking into the differences in susceptibility to ciprofloxacin and cefotaxime for a number of 
known risk factors for complicated UTI and ABR, significantly higher resistance were found 
in cultures from the surgical ward compared to the surgical reference clinic. In cases with 
indwelling urinary catheter and in cases with previous admittance to hospital, a statistically 
significant higher resistance to ciprofloxacin were found. This could probably be explained by 
a higher risk of (previously) being colonized by a strain of fluoroquinolone-resistant bacteria 
in an environment with a high presence of resistant bacteria. The lack of statistical significant 
differences between the other groups could be explained by the small number of cases in each 
group, or confounding factors. 
 
Part 1 
Although high levels of ABR were found for all pathogens to all antibiotics, especially 
worrying are the high rates of resistance against fluoroquinolones, which besides being the 
most used antibiotics in this study, also are a per oral (p.o.) antibiotic meaning it can be used 
in an out-patient settings. Co-trimoxazole – another p.o. drug – had in E. coli isolates a 
slightly lower resistance rate than fluoroquinolones. Nitrofurantoin (p.o), had a relatively low 
resistance rate in E. coli (24 % resistant, 13 % intermediate), but high for both Klebsiella spp 
and non-E. coli (over 80 % resistant). Third generation cephalosporins 
(cefotaxime/ceftriaxone, both intravenously [i.v.] administrated) had lower resistance rates 
than fluoroquinolones, although still high, and a pronounced difference between E. coli, 
Klebsiella spp and non-E. coli were noted. No testing for ESBL-producing bacteria were 
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conducted, but a study from Kathmandu in 2013 found 13.51 % of E. coli and 16.55 % of 
Klebsiella pneumoniae to be ESBL positive [37]. Amikacin (i.v.) had the lowest rates of 
resistance among all the commonly used antibiotics, and noticeably lower than gentamycin. 
No major differences were seen between E. coli, Klebsiella spp and non-E.coli.  
 
Carbapenems, piperacillin-tazobactam, colistin and tigecycline were only tested on a small 
number of isolates, and hence reliable conclusions cannot be made. However, colistin and 
tigecyclin seem to have low rates of resistance. On the other hand, the resistance to 
carbapenems appear to be around 50 %, a finding contradictory to other studies where no 
resistance to carbapenems have been found [1, 37]. This indicates a possible rise in resistance 
to carbapenems, and once again stresses the importance of ABR monitoring. No use of 
carbapenems, piperacillin-tazobactam, colistin or tigecycline was found in the studied medical 
records. This raises the question on the origin of the resistance to carbapenems found in this 
study. A study from New Delhi in 2011 found NDM-1-producing bacteria in drinking water 
and seepage samples, indicating a possibility of acquiring resistant bacteria outside of health-
care facilities, and this might be a possible origin, apart from other departments or health-care 
facilities [44]. 
 
Compared to previous studies from Nepal [36-38] and data from WHO [1], the susceptibility 
patterns were similar, although resistance rates were often higher in this study. In these 
studies the resistance of E. coli to fluoroquinolones were 35.9 % - 64.3 %, and to third 
generation cephalosporins 19.2 % - 37.9 %. In Klebsiella spp the resistance to 
fluoroquinolones were 4.3 % - 16.7 %, and to third generation cephalosporins 3.2 % - 48.3 %. 
However, different cephalosporins (ceftazidime, cefotaxime and ceftriaxone) were used in the 
different studies, making comparisons of resistance to cephalosporins somewhat uncertain. 
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Nitrofurantoin had a comparable resistance rate in [38], and a lower (7.9 %) in [36]. Amikacin 
were the antibiotic with highest susceptibility in all three studies [36-38].  
 
The findings in this study of high levels of ABR, especially considered together with the 
widespread use of fluoroquinolones and the low success rate of first line treatments, a change 
in empirical treatment of UTI in surgical patients at Patan Hospital could be advised. 
Fluoroquinolones and third generation cephalosporins should be avoided, both due to low 
probability of treatment success, and also to slow down even further increase in resistance. A 
high resistance to these antibiotics might increase the use of carbapenems, and with it the risk 
of increased resistance to them. As a p.o. treatment, nitrofurantoin could be used as a first line 
treatment in patients (including men) with uncomplicated, lower UTI without fever and with 
high probability of E. coli [13, 36, 37, 45]. Considering that the resistance to co-trimoxazole 
were similar to that of fluoroquinolones and third generation cephalosporins in E. coli 
isolates, it too could be considered as an alternative. When an i.v. drug is needed, amikacin 
seem to be the best alternative, with good effect on upper UTI and septicaemia and high 
susceptibility among all major pathogens [36, 37]. Nitrofurantoin and amikacin are also 
effective in cases of ESBL-producing pathogens [37, 45].  
 
Being a highly selected group of patients with a high prevalence of risk factors for increased 
ABR, conclusions and extrapolations to the general patient population should be done with 
cautions. However, a general shift in treatment of UTI towards nitrofurantoin and amikacin 
could be advised. The importance of culture and antibiotic susceptibility testing cannot be 
overstated. Since Patan Hospital accepts patients from all over the country, a widespread ABR 
in the hospital also implies the risk of people from remote areas acquiring resistant bacteria, 
and then may act as carriers of drug resistant pathogens back to their native areas.  
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In this study, a lesser percentages of cultures were positive compared to previous studies from 
Nepal. A study from Kathmandu had 30.8 % positive cultures in a hospital setting with a 
mixed study population of in- and out-patients [36], whereas a study from Pokhara found 71.1 
% positive cultures in hospitalized patients only [38]. It was in this study not possible to know 
if the patient was already on any kind of antibiotic, and whether this could be a contributing 
factor to the relatively low percentage of positive cultures. However, while there could be a 
number of other reasons contributing to the different figures, it shows the importance of 
culture in addition to patient history and clinical examination to confirm the diagnosis of UTI.  
 
The dominating bacteria found E. coli. In cultures with more than 100 000 CFU/ml E. coli 
made up 75 % of positive cultures, and in cultures from the surgical ward only the number 
were 69 %. This can be compared to 81.3 % in [36], and 59.4 % in [38]. In a North American 
and European material, E. coli made up 47 % and 36 % of positive cultures among 
hospitalized patients, respectively [46]. Among out-patients, E. coli often make up over 80 % 
of UTI [13]. This corresponds well with the conception that the proportion of complicated 
UTI caused by non-E. coli pathogens is higher in a hospital setting. Still, the proportion of E. 
coli in hospitalized patients in this study was relatively high. 
 
Part 2 
The success rate of the first line treatment reflects the high resistance rate. Only 55 % of cases 
treated with antibiotics were treated with at least one antibiotic that were effective against the 
bacteria. In many cases, the only effective antibiotic were an aminoglycoside, and since this is 
an i.v. drug and hence only can be administrated to admitted patients, the real effectiveness of 
the antibiotic treatment once the patient have been discharged is hard to determine and 
probably even somewhat lower than suggested. 17 % of cases had treatment failure and 
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received second-line treatment. This figure is however very uncertain since only antibiotics 
prescribed by PH are included, and if the patient sought medical attention elsewhere, or 
bought antibiotics over-the-counter, this is not included. 
 
Even though there are considerable room for improvement, improving the effectiveness of the 
antibiotic treatment is a daunting task in the light of the high rates of ABR. Clinical guidelines 
could play an important role in this work. As discussed above, an increased use of 
nitrofurantoin and amikacin could be advised. Empirical antibiotic treatment should be kept to 
a minimum, and if the patient’s condition allowing, antibiotic treatment could in certain 
circumstances await the culture result. Also, especially in patients with indwelling urinary 
catheter, antibiotic treatment should only be done when an actual UTI is suspected, and not 
only to treat a positive urine culture (i.e. ABU).  
 
The most common antibiotics used in this study – both as first-line treatment, in overall 
treatment and previously prescribed – were fluoroquinolones, ceftriaxone and 
aminoglycosides (amikacin and gentamycin equally used), which is consistent with reports on 
empirical treatment in PH [43]. Co-trimoxazole and nitrofurantoin were used only 
sporadically. To facilitate future studies on antibiotic prescription, a more systematic and 
standardized way of documentation should be implemented. This does not necessarily only be 
a part of the patient’s medical chart, but could be recorded for the whole ward/clinic together, 
and contain information as e.g. antibiotic prescription, indication, culture result etc. 
 
A peculiar finding is that in only 54 % of the cases signs and/or symptoms of UTI were noted 
in the medical chart. It is, however, hard to determine if the other 46 % of the cases actually 
had ABU, or if information in the charts simply were missing in some cases. To facilitate 
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future studies, a more meticulous and/or standardized recording of key information is 
recommended.  
 
A majority of the patients were men, contradictory to other studies [32, 36-38]. Females 
dominated in the younger ages and males in the older. Patients with some kind of urological 
condition as primary diagnosis dominated greatly, with surgical conditions and infections in a 
shared second place. Urological condition was also by far the most common secondary 
diagnosis. 40 % of the cases had an indwelling urinary catheter when the urine sample were 
taken, a majority of them being males. Use of indwelling urinary catheter, and surgical- and 
urological condition were associated with a statistically significant increased likelihood of 
non-E. coli pathogens. A large number of the cases had one or several risk factors for 
(complicated) UTI and/or ABR, such as previous instrumentation in the urinary tracts, 
previous surgery, previous admittance to hospital, previous UTI, and (multiple) previous 
antibiotics treatments.  
 
Study limitations 
The bacterial cultures in this study came from a selected group of patients with an 
overrepresentation of risk factors for complicated UTI and ABR, and the findings in this study 
are not applicable to community-acquired, uncomplicated UTI and UTI-patients in general. It 
is more likely that the pathogens found and their resistance patterns are representative of the 
bacteria circulating in the hospital than in the community at large. 
 
Both the log books and the medical charts were hand written. Even though the utmost care 
have been taken, misinterpretations cannot be ruled out due to the handwritten data and the 
language barrier. The medical charts were paper sheets stacked within a folder and there is a 
39 
 
possibility that sheets were missing. Also, the records are doctor-dependent and absence of 
information could be interpreted both as lack of recording or e.g. absence of symptoms.  
 
The inclusion criteria of over 100 000 CFU/ml is not used everywhere for UTI, e.g. the 
Swedish criteria for UTI differ (1, 6). It was in this study not possible to know if the patient 
was already on any kind of antibiotic, and whether this could be a contributing factor to the 
relatively low percentage of positive cultures. 
 
All cases in Part 2 had positive urine cultures, hence there is no control group to compare 
with. The dropout rate was high, reasons for that could be that the medical charts was 
misplaced or that the number recorded was incorrectly or unclear. Not all cases had follow-up 
to evaluate treatment success. This made conclusions about outcome were hard to draw. Also, 
since only the medical charts from Patan Hospital were available, it is not possible to know if 
the patients were treated at other health-care facilities, or bought antibiotics over-the-counter. 
 
Information about the antibiotics prescribed was limited to type of antibiotic and first day of 
prescription, and not duration, dose, or re-prescription. Hence, conclusions about the 
treatment are somewhat uncertain. Many patients had other infections and conditions 
requiring antibiotics, and the indications for each antibiotic were most often not possible to 
determine.  
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CONCLUSIONS 
The findings in this study show an exceptionally high rate of ABR in the surgical department 
of Patan Hospital, and a low rate of effective empirical antibiotic treatment. To tackle this 
problem both national and local guidelines are needed to ensure effective (empirical) 
treatment and to hold back an even further increase in ABR. Empirical treatment should be 
minimized, and an increased use of nitrofurantoin and amikacin is recommended since these 
two drugs showed the lowest resistance rates (nitrofurantoin in E. coli, amikacin in all 
pathogens). Since rates of ABR can vary between settings and over time, a throughout local 
surveillance of ABR can play an important role in helping clinicians choose the optimal 
empiric antibiotic treatment and also be an important tool to hamper further increase of ABR. 
Further studies are needed in other departments, hospitals and out-patients settings. Further 
studies are also needed on outcome of antibiotic treatment, and to determine if – and to what 
degree – ABR is a threat to patient wellbeing and survival.  
 
POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA 
Urinvägsinfektioner är en av de vanligaste infektionerna hos människor. Det är också en 
mycket vanlig orsak till förskrivning av antibiotika. På grund av detta spelar 
urinvägsinfektioner en stor roll för uppkomst och spridning av bakterier som är okänsliga för 
antibiotika. Okänsliga bakterier kan göra infektioner svårbehandlade med de antibiotika som 
vanligen används. Denna studie undersökte urinvägsinfektioner på en kirurgklinik på ett 
sjukhus i utkanten av Kathmandu i Nepal. Bland de bakterier som hittades var en hög andel 
okänsliga mot de antibiotika som vanligen användes. Det kan bero på att många patienter 
hade flera olika riskfaktorer för att få en infektion med en okänslig bakterie. Endast 55 % av 
behandlade patienter fick i första behandlingsomgången en antibiotika som var effektiv. 
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Patienter som var inneliggande på avdelning, hade urinkateter eller tidigare hade varit inlagda 
på sjukhuset hade högre risk att vara infekterade med en okänslig bakterie. Utifrån fynden i 
denna studie kan det rekommenderas att utföra en bakterieodling innan behandling, att om 
möjligt avvakta med antibiotikabehandling tills odlingssvar föreligger, samt att öka 
användningen av vissa antibiotika. Kunskap om andelen okänsliga bakterier är viktigt och kan 
hjälpa läkare att välja rätt antibiotika. Rätt antibiotika kan göra behandlingen effektivare och 
bromsa uppkomsten av okänsliga bakterier. Fler studier där man undersöker okänsliga 
bakterier på andra avdelningar, på andra sjukhus och inte minst i öppenvården behövs. 
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